Clinical Pharmacokinetics

, Volume 52, Issue 1, pp 1–8 | Cite as

The Clinical Relevance of Plasma Protein Binding Changes

Current Opinion

Abstract

Controversy reigns as to how protein binding changes alter the time course of unbound drug concentrations in patients. Given that the unbound concentration is responsible for drug efficacy and potential drug toxicity, this area is of significant interest to clinicians and academics worldwide. The present uncertainty means that many questions relating to this area exist, including “How important is protein binding?”, “Is protein binding always constant?”, “Do pH and temperature changes alter binding?” and “How do protein binding changes affect dosing requirements?”. In this paper, we seek to address these questions and consider the data associated with altered pharmacokinetics in the presence of changes in protein binding and the clinical consequences that these may have on therapy, using examples from the critical care area. The published literature consistently indicates that a change in the protein binding and unbound concentrations of some drugs are common in certain specific patient groups such as the critically ill. Changes in pharmacokinetic parameters, including clearance and apparent volume of distribution (Vd), may be dramatic. Drugs with high protein binding, high intrinsic clearance (e.g. clearance by glomerular filtration) and where dosing is not titrated to effect are most likely to be affected in a clinical context. Drugs such as highly protein bound antibacterials with multiple half-lives within a dosing interval and that have some level of renal clearance, such as ertapenem, teicoplanin, ceftriaxone and flucloxacillin, are commonly affected. In response to these challenges, clinicians need to adapt dosing regimens rationally based on the pharmacokinetic/pharmacodynamic characteristics of the drug. We propose that further pharmacokinetic modelling-based research is required to enable the design of robust dosing regimens for drugs affected by altered protein binding.

References

  1. 1.
    Namendys-Silva SA, Gonzalez-Herrera MO, Texcocano-Becerra J, Herrera-Gomez A. Hypoalbuminemia in critically ill patients with cancer: incidence and mortality. Am J Hosp Palliat Care. 2011;28(4):253–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Ensom MH. Comment: unbound drug concentration versus unbound drug fraction. Ann Pharmacother. 2002;36(4):731–2. (author reply 732).PubMedCrossRefGoogle Scholar
  3. 3.
    Toutain PL, Bousquet-Melou A. Free drug fraction vs. free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther. 2002;25(6):460–3.PubMedCrossRefGoogle Scholar
  4. 4.
    Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929–39.PubMedCrossRefGoogle Scholar
  5. 5.
    Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99–110.PubMedCrossRefGoogle Scholar
  6. 6.
    Burton ME, Shaw LM, Schentag JJ, Evans WE. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. 4th ed. Baltimore: Lippincott Williams and Wilkins; 2006.Google Scholar
  7. 7.
    Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother. 1991;35(10):1953–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Barbot A, Venisse N, Rayeh F, Bouquet S, Debaene B, Mimoz O. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med. 2003;29(9):1528–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, Paterson DL, et al. Antibiotic dosing in the ‘at risk’ critically ill patient: linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol. 2011;11:3.PubMedCrossRefGoogle Scholar
  10. 10.
    Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther. 1981;29(5):650–7.PubMedCrossRefGoogle Scholar
  11. 11.
    MacKichan JJ, Zola EM. Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol. 1984;18(4):487–93.PubMedCrossRefGoogle Scholar
  12. 12.
    Finfer S, Bellomo R, McEvoy S, Lo SK, Myburgh J, Neal B, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ. 2006;333(7577):1044.PubMedCrossRefGoogle Scholar
  13. 13.
    Ulldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother. 2010;65(8):1771–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Brink AJ, Richards GA, Schillack V, Kiem S, Schentag J. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents. 2009;33(5):432–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Douglas A, Altukroni M, Udy AA, Roberts MS, Taraporewalla K, Jenkins J, et al. The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery. BMC Anesthesiol. 2011;11:5.PubMedCrossRefGoogle Scholar
  16. 16.
    Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother. 2001;47(4):421–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Pea F, Brollo L, Lugano M. Dal Pos L, Furlanut M. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Ther Drug Monit. 2001;23(5):587–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Pea F, Viale P, Candoni A, Pavan F, Pagani L, Damiani D, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet. 2004;43(6):405–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Burney RG, DiFazio CA, Foster JA. Effects of pH on protein binding of lidocaine. Anesth Analg. 1978;57(4):478–80.PubMedCrossRefGoogle Scholar
  20. 20.
    Hinderling PH, Hartmann D. The pH dependency of the binding of drugs to plasma proteins in man. Ther Drug Monit. 2005;27(1):71–85.PubMedCrossRefGoogle Scholar
  21. 21.
    Paxton JW, Calder RL. Propranolol binding in serum: comparison of methods and investigation of effects of drug concentration, pH, and temperature. J Pharmacol Methods. 1983;10(1):1–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Kochansky CJ, McMasters DR, Lu P, Koeplinger KA, Kerr HH, Shou M, et al. Impact of pH on plasma protein binding in equilibrium dialysis. Mol Pharm. 2008;5(3):438–48.PubMedCrossRefGoogle Scholar
  23. 23.
    Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115–21.PubMedCrossRefGoogle Scholar
  24. 24.
    Rolan PE. Plasma protein binding displacement interactions: why are they still regarded as clinically important? Br J Clin Pharmacol. 1994;37(2):125–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf. 1995;12(4):227–33.PubMedCrossRefGoogle Scholar
  26. 26.
    Swabb EA, Leitz MA, Pilkiewicz FG, Sugerman AA. Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects. J Antimicrob Chemother. 1981;8 Suppl E:131–40.Google Scholar
  27. 27.
    Janicke DM, Cafarell RF, Parker SW, Apicella MA, Jusko WJ. Pharmacokinetics of aztreonam in patients with gram-negative infections. Antimicrob Agents Chemother. 1985;27(1):16–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Dvorchik B, Sica D, Gehr T. Pharmacokinetics and safety of single-dose daptomycin in subjects with graded renal insufficiency and end-stage renal disease [poster]. Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 2002. pp. 27–31.Google Scholar
  29. 29.
    Mohr JF 3rd, Ostrosky-Zeichner L, Wainright DJ, Parks DH, Hollenbeck TC, Ericsson CD. Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother. 2008;52(5):1891–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Pletz MW, Rau M, Bulitta J, De Roux A, Burkhardt O, Kruse G, et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother. 2004;48(10):3765–72.PubMedCrossRefGoogle Scholar
  31. 31.
    Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother. 2007;59(2):277–84.PubMedCrossRefGoogle Scholar
  32. 32.
    Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M, Bulitta JB, Holzgrabe U, Drusano GL, et al. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob Agents Chemother. 2007;51(9):3290–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Taburet AM, Guibert J, Kitzis MD, Sorensen H, Acar JF, Singlas E. Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation. J Antimicrob Chemother. 1990;25 Suppl B:23–31.Google Scholar
  34. 34.
    Peter JD, Jehl F, Pottecher T, Dupeyron JP, Monteil H. Pharmacokinetics of intravenous fusidic acid in patients with cholestasis. Antimicrob Agents Chemother. 1993;37(3):501–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Outman WR, Nightingale CH, Sweeney KR, Quintiliani R. Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses. Antimicrob Agents Chemother. 1990;34(11):2114–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Tincani E, Mazzali F, Morini L. Hypoalbuminemia as a risk factor for over-anticoagulation. Am J Med. 2002;112(3):247–8.PubMedCrossRefGoogle Scholar
  37. 37.
    McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JP. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(22):2039–43.PubMedCrossRefGoogle Scholar
  38. 38.
    Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J. Augmented renal clearance in the intensive care unit: an illustrative case series. Int J Antimicrob Agents. 2010;35(6):606–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1–16.PubMedCrossRefGoogle Scholar
  40. 40.
    Udy AA, Roberts JA, Dewaele JJ, Paterson DL, Lipman J. What’s behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents. 2012;39(6):455–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney B, Ungerer J, et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142(1):30–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36(4):332–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis. 2006;42(12):1764–71.PubMedCrossRefGoogle Scholar
  44. 44.
    Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44(10):1009–34.PubMedCrossRefGoogle Scholar
  45. 45.
    Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol. 2011;12(12):2070–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45(8):755–73.PubMedCrossRefGoogle Scholar
  47. 47.
    Ulldemolins M, Roberts JA, Lipman J, Rello J. Antibiotic dosing in multiple organ dysfunction syndrome. Chest. 2011;139(5):1210–20.PubMedCrossRefGoogle Scholar
  48. 48.
    Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14(4):R126.PubMedCrossRefGoogle Scholar
  49. 49.
    Pea F, Pavan F, Furlanut M. Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. Clin Pharmacokinet. 2008;47(7):449–62.PubMedCrossRefGoogle Scholar
  50. 50.
    Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA. Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care. 2012;2(1):35.PubMedCrossRefGoogle Scholar
  51. 51.
    Burian A, Wagner C, Stanek J, Manafi M, Bohmdorfer M, Jager W, et al. Plasma protein binding may reduce antimicrobial activity by preventing intra-bacterial uptake of antibiotics, for example clindamycin. J Antimicrob Chemother. 2011;66(1):134–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Tillement JP, Lhoste F, Giudicelli JF. Diseases and drug protein binding. Clin Pharmacokinet. 1978;3(2):144–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2012

Authors and Affiliations

  • Jason A. Roberts
    • 1
    • 2
    • 3
  • Federico Pea
    • 4
  • Jeffrey Lipman
    • 1
    • 2
  1. 1.Burns, Trauma and Critical Care Research CentreThe University of QueenslandBrisbaneAustralia
  2. 2.Department of Intensive Care MedicineRoyal Brisbane and Women’s HospitalBrisbaneAustralia
  3. 3.Pharmacy DepartmentRoyal Brisbane and Women’s HospitalBrisbaneAustralia
  4. 4.Department of Experimental and Clinical Medicine, Institute of Clinical Pharmacology and ToxicologyAzienda Ospedaliero-Universitaria Santa Maria della Misericordia, University of UdineUdineItaly

Personalised recommendations